Business Wire

Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 2026

15.9.2026 14:00:00 EEST | Business Wire | Press release

Share

Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes.

From AI Potential to Operational Impact

As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat Gaurav and Executive Vice President, EMEA, Fabienne Cêtre, will open the mainstage with an exploration of the market forces reshaping global supply chains and how operational orchestration is helping organizations bridge that gap by connecting people, processes, data, and AI across the enterprise. This welcome session will be livestreamed globally.

The mainstage program will offer a look at the technologies reshaping supply chain and how AI is evolving from a decision-support tool into an operational partner.

  • Andrew Bell, Chief Product Officer, will showcase what’s ahead for Kinaxis, including the continued evolution of Maestro and a closer look at how innovations in AI-powered orchestration will help supply chain teams respond faster and align decisions across functions.
  • Manik Sharma, Chief of Agentic Solutions, will build on this with a deeper look at how forward deployed engineering (FDE) teams are working alongside organizations to move agentic AI into real enterprise environments and accelerate measurable value.

“Supply chains are operating in an environment where the speed and complexity of decision-making have fundamentally changed,” said Razat Gaurav, CEO of Kinaxis. “AI is creating an entirely new frontier for supply chain, but technology alone doesn’t create business value. At Kinexions North America, we introduced our vision for operational orchestration to move from decisions to outcomes in a more connected way. Since then, we’ve been turning that vision into real capabilities for our customers and partners globally. In Barcelona, we’ll show attendees how it’s becoming a reality and what it means for the future of supply chain.”

Keynote: Human Performance in an AI-Powered World

Taking the stage as the featured keynote speaker is Dr. James Hewitt, human performance scientist, author, and expert on performance under pressure. Drawing on research spanning Formula 1 to Fortune 500 organizations, Hewitt will explore why human judgment and trust matter more as AI takes on greater autonomy. That balance between human judgment and intelligent technology will carry throughout the event as Kinaxis explores what an increasingly agentic world means for the future of the supply chain industry and its leaders.

Three Days of Insight, Innovation and Community

Attendees will hear directly from global leaders at Bosch, Castrol, Coca-Cola Al Ahlia Beverages, Moët Hennessy and more about how they are navigating complex global supply chains, volatility and changing business demands. Kinexions EMEA will offer dedicated product showcases, expert-led sessions and hands-on bootcamps to move the conversation from concept to experience, giving attendees the opportunity to explore the technologies and approaches behind Kinaxis' vision for operational orchestration. The program will also offer opportunities to connect with partners and peers, along with the Women in Supply Chain Breakfast, a dedicated forum for leadership and celebrating the women helping to move the industry forward.

Kinexions EMEA 2026 takes place October 26–28 at the Grand Hyatt Barcelona.

View the agenda HERE
Registration is open HERE

About Kinaxis

Kinaxis is a leader in modern supply chain planning and orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Source: Kinaxis Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915788515/en/

Contacts

Media Relations
Erin Boyle | Kinaxis
eboyle@kinaxis.com
+1 519-574-4065

Investor Relations
Victoria Hyde-Dunn | Kinaxis
vhyde-dunn@kinaxis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo ® ) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 09:00:00 EEST | Press release

Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one of the largest real-world evaluations of mogamulizumab in Germany and add to the growing body of evidence supporting its use in routine clinical practice.1-3 Conducted as a company-sponsored, multicentric, non-interventional, combined retro-prospective real-world study across 18 centres throughout Germany, MINT brought together cutaneous T‑cell lymphoma (CTCL) specialists to evaluate treatment outcomes with mogamulizumab in a real-world setting, with time-to-next-treatment (TTNT) as the study’s primary endpoint.1 The study captured a broad and heterog

Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 09:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural next step for Megaport. “Portugal’s digital economy is rapidly growing, and infrastructure is at the heart of that transfor

Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 19:09:00 EEST | Press release

Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,

Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 13:30:00 EEST | Press release

As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged

Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye